NDA 218436 · Novartis
Rhapsido
Remibrutinib · Oral
NovelPriority reviewCDER novel approval, Sep 30, 2025: To treat chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Sep 30, 2025
Approved uses
2
Original approval plus efficacy supplements
Registered trials
34
22 Phase 3, 12 recruiting
FAERS reports
1,354
267 serious, 1 with death reported
AI brief across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 6, 2026 Supplement 1 · Efficacy LetterLabel
- Sep 30, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
- RHAPSIDO · REMIBRUTINIB 25MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Remibrutinib" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07225504 · 1,275 participants (planned) · Start Nov 11, 2025 · Primary completion Dec 3, 2030
Drug: Remibrutinib (blinded); Placebo and 1 more · For: Secondary Progressive Multiple Sclerosis (SPMS)
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 296 sites in all
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05156281 · 1,007 participants · Start Dec 13, 2021 · Primary completion Jul 22, 2026
Drug: Remibrutinib; Teriflunomide · For: Relapsing Multiple Sclerosis
Sites: Phoenix, Arizona; Hanford, California; Los Angeles, California · 223 sites in all
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05147220 · 1,000 participants · Start Dec 16, 2021 · Primary completion Jul 21, 2026
Drug: Remibrutinib; Teriflunomide · For: Relapsing Multiple Sclerosis
Sites: Phoenix, Arizona; Tucson, Arizona; Fort Smith, Arkansas · 200 sites in all
- An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07665437 · 710 participants (planned) · Start Jul 10, 2026 · Primary completion Oct 15, 2031
Drug: Remibrutinib · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Fort Smith, Arkansas; North Little Rock, Arkansas · 61 sites in all
- An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With RemibrutinibPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05513001 · 696 participants · Start Dec 9, 2022 · Primary completion Aug 26, 2024
Drug: LOU064 (blinded); Placebo and 1 more · For: Chronic Spontaneous Urticaria
Sites: Birmingham, Alabama; Litchfield Park, Arizona; Little Rock, Arkansas · 208 sites in all
- Remibrutinib Open Label Roll-over Post-trial Access ProtocolPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07456891 · 650 participants (planned) · Start Apr 16, 2026 · Primary completion Jan 30, 2033
Drug: Remibrutinib · For: Indication of the Parent Protocol
Sites: Sofia, Bulgaria; Varna, Bulgaria; Fredericton, Canada · 46 sites in all
- A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06799000 · 588 participants · Start Jan 31, 2025 · Primary completion May 17, 2027
Drug: Remibrutinib Dose A; Remibrutinib Dose B and 2 more · For: Hidradenitis Suppurativa
Sites: Phoenix, Arizona; Fort Smith, Arkansas; North Little Rock, Arkansas · 139 sites in all
- A 52-week Study of Remibrutinib in IgE-mediated Food AllergyPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07768371 · 576 participants (planned) · Start Aug 27, 2026 · Primary completion Mar 30, 2029
Drug: Remibrutinib; Placebo · For: IgE-Mediated Food Allergy; Peanut Allergy; Cow Milk Allergy and 1 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 22 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- urticaria186
- petechiae185
- drug ineffective148
- contusion130
- pruritus105
- headache77
- heavy menstrual bleeding59
- nausea58
- off label use57
- condition aggravated53
- chronic spontaneous urticaria44
- rash40
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 9 |
| 2025 | 234 |
| 2026 | 1,111 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Remibrutinib in Chronic Spontaneous Urticaria.
Metz M, Giménez-Arnau A, Hide M, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Multicenter Study
- Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies.
Giménez-Arnau AM, Szalewski R, Hide M, et al. · J Allergy Clin Immunol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis.
Chu AWL, Oykhman P, Chu X, et al. · J Allergy Clin Immunol 2025 · Comparative Study, Network Meta-Analysis
- Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.
Maurer M, Berger W, Giménez-Arnau A, et al. · J Allergy Clin Immunol 2022 · Randomized Controlled Trial
- Efficacy, Safety, and Quality-of-Life Outcomes of Remibrutinib in Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis.
Khan AA, Riaz AA, Naseer F, et al. · J Allergy Clin Immunol Pract 2025 · Systematic Review, Meta-Analysis
- Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2.
Mosnaim G, Saini S, Lebwohl M, et al. · Ann Allergy Asthma Immunol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.